Topaz Clinical Research — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Topaz Clinical Research is a private, mid-sized CRO operating in the highly competitive clinical trial services market. As a service provider, it generates revenue by contracting its operational expertise to sponsor companies, positioning it in the 'Revenue Generating' category. Its success hinges on efficient trial execution, robust patient recruitment networks, and maintaining strong client relationships in a cost-conscious industry.

Clinical ResearchDrug Development

Technology Platform

Integrated operational suite for clinical trial management, including CTMS, EDC, and proprietary patient recruitment analytics and outreach tools.

Opportunities

Growing biopharma R&D outsourcing trend, especially from capital-efficient small and mid-sized biotechs.

Increasing industry focus on solving patient recruitment bottlenecks presents a direct demand for its specialized services.

Potential to expand service offerings into high-growth areas like decentralized trial support and real-world evidence generation.

Risk Factors

High dependence on a limited client base and cyclical biopharma R&D budgets.

Intense competition from large global CROs and niche players pressures pricing and margins.

Operational failure or regulatory non-compliance on a client trial could lead to significant reputational and financial damage.

Competitive Landscape

Topaz competes in a crowded and fragmented CRO market dominated by large, full-service global players (e.g., IQVIA, Labcorp) and numerous small to mid-sized specialized firms. Competition is based on cost, therapeutic expertise, service quality, and technological capability. Differentiation is critical for mid-tier CROs like Topaz to avoid being marginalized.

More companies in Digital Health & Biotech SaaS →More companies in United States →